Sudbury, MA, United States of America

Lesile D Lowe

This inventor holds 1 USPTO granted patent. Top assignee: Genetics Institute, Inc.. Active years: 2007.


Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lesile D. Lowe: Innovator in Immunology

Introduction

Lesile D. Lowe is a notable inventor based in Sudbury, MA (US). He has made significant contributions to the field of immunology through his innovative research and patent work. His expertise lies in developing methods that can potentially alter immune responses, which is crucial for various medical applications.

Latest Patents

Lesile D. Lowe holds a patent titled "Methods of treatment with antagonists of MU-1." This patent describes a method for suppressing an immune response in a subject by administering an antagonist of a MU-1 hematopoietin receptor superfamily chain protein. This innovative approach has the potential to impact treatments for conditions where immune response modulation is necessary.

Career Highlights

Lowe is associated with Genetics Institute, Inc., where he has been involved in groundbreaking research. His work has contributed to the understanding of immune mechanisms and the development of therapeutic strategies. With 1 patent to his name, he has established himself as a key figure in his field.

Collaborations

Throughout his career, Lesile D. Lowe has collaborated with notable colleagues, including Matthew James Whitters and Debra D. Donaldson. These collaborations have fostered a productive research environment, leading to advancements in immunological treatments.

Conclusion

Lesile D. Lowe's contributions to immunology through his patent and collaborative efforts highlight his role as an innovator in the field. His work continues to pave the way for new therapeutic approaches in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…